WST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (
NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical and certain of West Pharmaceutical’s current and former top executives with violations of the Securities Exchange Act of 1934.
WST Investors Have Opportunity to Lead West Pharmaceutical Services, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. (“West” or “the Company”) (
NYSE: WST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (“West” or the “Company”) (
NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against West Pharmaceutical Services, Inc. and Certain of Its Executives
Labaton Keller Sucharow LLP (“Labaton”) announces that, on May 5, 2025, it filed a securities class action lawsuit (the “Complaint”) on behalf of its client the New England Teamsters Pension Fund (“New England Teamsters”) against West Pharmaceutical Services, Inc. (“West” or the “Company”) (
NYSE: WST) and certain West executives (collectively, “Defendants”). The action, which is captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.) asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons and entities that purchased or otherwise acquired West common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”).
3 Dividend Champions with room for dividend growthDividend Champions that have payout ratios below 20%, like these three stocks, can be an incredibly compelling choice for buy-and-hold dividend investors.
Sotera Health Appoints Karen Flynn to Board of DirectorsCLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.
West Pharmaceutical Services Inc. (NYSE: WST) Sets New 52-Week High in Tuesday SessionShares of West Pharmaceutical Services, Inc. (
NYSE: WST) traded at a new 52-week high today and are currently trading at $395.02. So far today, approximately 202.24k shares have been exchanged, as compared to an average 30-day volume of 391.02k shares.
What Factors Will Drive S&P 500 Performance This Year?Analysts are forecasting a positive return for the S&P 500, and back-to-back downside years are rare. But weakening earnings could put a dent in returns.
Healthcare Stocks With at Least 30 Years of Dividend IncreasesAmong the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.
